Original Research

Published on 10 Mar 2022

PD-L1 Antibody Pharmacokinetics and Tumor Targeting in Mouse Models for Infectious Diseases

in Cancer Immunity and Immunotherapy

Gerwin G. W. Sandker
Gosse Adema
Janneke Molkenboer-Kuenen
Peter Wierstra
Johan Bussink
Sandra Heskamp
Erik H. J. G. Aarntzen

Frontiers in Immunology

doi 10.3389/fimmu.2022.837370

4,953 views
6 citations

Mini Review

Published on 05 Sep 2022

Overcoming resistance to PD-1/PD-L1 inhibitors in esophageal cancer

in Pharmacology of Anti-Cancer Drugs

Chao Cheng
Lingdun Zhuge
Xin Xiao
Siyuan Luan
Yong Yuan

Frontiers in Oncology

doi 10.3389/fonc.2022.955163

3,470 views
8 citations

Review

Published on 27 Aug 2019

PD-L1 Distribution and Perspective for Cancer Immunotherapy—Blockade, Knockdown, or Inhibition

in Cancer Immunity and Immunotherapy

Yilun Wu
Weiyu Chen
Zhi Ping Xu
Wenyi Gu

Frontiers in Immunology

doi 10.3389/fimmu.2019.02022

56,748 views
293 citations

Original Research

Published on 27 Apr 2021

Performance of Different Diagnostic PD-L1 Clones in Head and Neck Squamous Cell Carcinoma

in Pathology

Julika Ribbat-Idel
Franz F. Dressler
Rosemarie Krupar
Christian Watermann
Finn-Ole Paulsen
Patrick Kuppler
Luise Klapper
Anne Offermann
Barbara Wollenberg
Dirk Rades

Frontiers in Medicine

doi 10.3389/fmed.2021.640515

6,263 views
14 citations

Original Research

Published on 20 Feb 2020

Upregulation of PD-L1 Expression by Prostaglandin E2 and the Enhancement of IFN-γ by Anti-PD-L1 Antibody Combined With a COX-2 Inhibitor in Mycoplasma bovis Infection

in Veterinary Infectious Diseases

Shinya Goto
Satoru Konnai
Yuki Hirano
Junko Kohara
Tomohiro Okagawa
Naoya Maekawa
Yamato Sajiki
Kei Watari
Erina Minato
Atsuhi Kobayashi

Frontiers in Veterinary Science

doi 10.3389/fvets.2020.00012

5,093 views
24 citations

Original Research

Published on 05 Dec 2022

Targeting 4-1BB and PD-L1 induces potent and durable antitumor immunity in B-cell lymphoma

in Cancer Immunity and Immunotherapy

Yichen Wang
Xuyao Zhang
Caili Xu
Yanyang Nan
Jiajun Fan
Xian Zeng
Byoung S. Kwon
Dianwen Ju

Frontiers in Immunology

doi 10.3389/fimmu.2022.1004475

3,287 views

Clinical Trial

Published on 20 Dec 2022

Translational analysis and final efficacy of the AVETUX trial – Avelumab, cetuximab and FOLFOX in metastatic colorectal cancer

in Cancer Genetics

Joseph Tintelnot
Inka Ristow
Markus Sauer
Donjete Simnica
Christoph Schultheiß
Rebekka Scholz
Eray Goekkurt
Lisa von Wenserski
Edith Willscher
Lisa Paschold

Frontiers in Oncology

doi 10.3389/fonc.2022.993611

3,024 views
10 citations

Navigation group

Articles

PD-L1 Antibody Pharmacokinetics and Tumor Targeting in Mouse Models for Infectious Diseases

Overcoming resistance to PD-1/PD-L1 inhibitors in esophageal cancer

PD-L1 Distribution and Perspective for Cancer Immunotherapy—Blockade, Knockdown, or Inhibition

Performance of Different Diagnostic PD-L1 Clones in Head and Neck Squamous Cell Carcinoma

Upregulation of PD-L1 Expression by Prostaglandin E2 and the Enhancement of IFN-γ by Anti-PD-L1 Antibody Combined With a COX-2 Inhibitor in Mycoplasma bovis Infection

Targeting 4-1BB and PD-L1 induces potent and durable antitumor immunity in B-cell lymphoma

Translational analysis and final efficacy of the AVETUX trial – Avelumab, cetuximab and FOLFOX in metastatic colorectal cancer